Brief: Il Dong Pharmaceutical Says S.Korea Ministry Of Food And Drug Safety Accepts Second Phase Clinical Trials For Covid-19 Oral Treatment
26/08/2022 02:00
Aug 26 (Reuters) - Il Dong Pharmaceutical Co Ltd
249420.KS :
* S.KOREA MINISTRY OF FOOD AND DRUG SAFETY ACCEPTS SECOND
PHASE
CLINICAL TRIALS FOR COVID-19 ORAL TREATMENT
Further company coverage: 249420.KS
(Reporting by Joyce Lee)
((JungYoon.Lee@thomsonreuters.com;))
Recent news on Il Dong Pharmaceutical
See all newsBrief: Il Dong Pharmaceutical Q4 Operating Profit 8 Billion Won, Down 5.7% From Year Earlier
To Divest 15.85 Billion Won Worth Of Shares In D&D Pharmatech
Brief: Il Dong Pharmaceutical Q3 Operating Profit 6.8 Billion Won, Up 87.6% From Year Earlier
Brief: Il Dong Pharmaceutical Q2 Operating Profit 596 Million Won, Down 41.4% From Year Earlier
Brief: Il Dong Pharmaceutical Q1 Operating Profit 4.2 Billion Won, Up 4275% From Year Earlier